Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Q4 2023 vs. Q3 2023
How the institutions holding Vaxcyte, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 202 | 223 | +21 |
| Shares | 101.4M | 103.1M | +1.71M (+1.7%) |
| Value | $5.17B | $6.47B | +$1.31B (+25.3%) |
New holders (37)
Institutions that held Vaxcyte, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (16)
Institutions that held Vaxcyte, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53.5M |
| Ikarian Capital, LLC | 142,417 | $7.26M |
| Maven Securities LTD | 67,500 | $3.44M |
| Readystate Asset Management LP | 58,472 | $2.98M |
| Trexquant Investment LP | 43,329 | $2.21M |
| Lisanti Capital Growth, LLC | 34,970 | $1.78M |
| SG Americas Securities, LLC | 27,980 | $1.43M |
| Boothbay Fund Management, LLC | 27,919 | $1.42M |
| Citadel Advisors LLC | 22,106 | $1.13M |
| EAM Investors, LLC | 17,289 | $881.4K |
| Graham Capital Management, L.P. | 7,082 | $361.0K |
| XTX Topco Ltd | 4,696 | $239.4K |
| Manchester Capital Management LLC | 1,500 | $76.5K |
| TSFG, LLC | 7 | $1.00K |
| Huntington National Bank | 18 | $918 |
| Massmutual Trust Co FSB | 6 | $306 |